Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease.

Of note, in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial, there was a nominally significant reduction in risk in the primary composite endpoint (time to death, myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular event) with cinacalcet treatment in patients with moderate-to-severe hyperparathyroidism receiving maintenance hemodialysis after adjustment for baseline characteristics [ 7 ].

also in 7,732 other papers